Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Evaluation of tumor response to paclitaxel treatment in breast cancer xenograft with 99mTc-labeled duramycin

Feng Wang, ZiZheng Wang and Rui Luo
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 1384;
Feng Wang
1Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZiZheng Wang
1Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rui Luo
1Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1384

Objectives Duramycin binds PE with high affinity and specificity. the goal was to investigate 99mTc-labeled duramycin for monitoring tumor response to Paclitaxel treatment in breast cancer xenograft.

Methods Duramycin is covalently modified with succinimidyl 6-hydrazinonicotinate acetone hydrazone (HYNIC) and labeled with 99mTc using a coordination chemistry . The binding of 99mTc-Duramycin toward apoptosis was validated in vitro using pactaxel-induced MDB-MA-231 tumor cells. MDB-MA-231 xenografts were divided into two groups randomly, one group receive single dose of paclitaxel (40mg/kg) treatment, the control receive the same volume of saline . After injection of 99mTc-duramycinby tail vein, micro SPECT/CTwere performed at 1,2h,respectively. Radioactivity in different tissues was determined after imaging. Apoptotic cells were measured with flow cytometry. Morphological changes ofapoptosis were observed by transmission electron microscopies. The data were analyzed by SPSS 19.0.

Results The radiochemical purity of 99mTc-Duramycin was > 95%. The predominant uptake was found in kidney, rapid clearance was observed in the blood and kidney. The ratio of tumor to muscle (T/NT) in treated group was 4.21±0.06, significantly higher than that of control (1.57±0.67,p<0.05,). Regarding the retention percentages of radioactivity (%ID/g) in tumor tissue at 48 hours later in treatment group was 4.82±0.54, significant higher than that of control (1.44±0.38). The tumor uptake of 99mTc-hynic-Duramycin of treatment correlated well with Annexin V/PI-positive cells in the tumor. Histopathology and ultrastructural changes further confirmed that the tumor radiouptake was caused by tumor apoptosis induced by chemotherapy , not by nonspecific uptake.

Conclusions Our data demonstrate the feasibility of 99mTc-duramycin for the early detection of apoptosis after pactaxel chemotherapy in breast xenografts. 99mTc-duramycin which derived with lantibiotics with low molecular weight ,unique three dimensional structure , might serve as a potential probe to detect cell death.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 55, Issue supplement 1
May 2014
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of tumor response to paclitaxel treatment in breast cancer xenograft with 99mTc-labeled duramycin
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Evaluation of tumor response to paclitaxel treatment in breast cancer xenograft with 99mTc-labeled duramycin
Feng Wang, ZiZheng Wang, Rui Luo
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 1384;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of tumor response to paclitaxel treatment in breast cancer xenograft with 99mTc-labeled duramycin
Feng Wang, ZiZheng Wang, Rui Luo
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 1384;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • The frequency and content of documentation for patients’ 131I therapies for checkpoint security agents: the final report of a national survey.
  • Radiopeptide Therapy using Lu-177 3BP-227 in a Patient with Pancreatic Adenocarcinoma
  • Comparing two methods for 90Y PET based dosimetry as a predictor of metabolic response for patients receiving radioembolisation
Show more Oncology: Basic, Translational & Therapy

MTA I: Oncology Basic, Basic Science Posters

  • In a large animal pre-clinical model, SSTR2-based reporter imaging demonstrates that angiotensin II improves gene expression upon intra-arterial adenovirus delivery
  • In vivo pharmacokinetic evaluation and PET imaging of gold nanocages for melanoma
  • Evaluation of dynamic changes in tumor hypoxia and proliferation after radiotherapy in human head and neck cancer xenograft using dual tracers of FMISO and FLT
Show more MTA I: Oncology Basic, Basic Science Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire